Literature DB >> 31688942

Biallelic DMXL2 mutations impair autophagy and cause Ohtahara syndrome with progressive course.

Alessandro Esposito1,2, Antonio Falace3, Matias Wagner4,5,6, Moran Gal7, Davide Mei3, Valerio Conti3, Tiziana Pisano3, Davide Aprile2, Maria Sabina Cerullo1,2, Antonio De Fusco1,2, Silvia Giovedì2, Annette Seibt8, Daniella Magen9,10, Tilman Polster11, Ayelet Eran9,12, Sarah L Stenton4,5, Chiara Fiorillo13,14, Sarit Ravid9,15, Ertan Mayatepek8, Hava Hafner9,16, Saskia Wortmann4,5,17, Erez Y Levanon7, Carla Marini3, Hanna Mandel9,18, Fabio Benfenati1,19, Felix Distelmaier8, Anna Fassio2,19, Renzo Guerrini3,20.   

Abstract

Ohtahara syndrome, early infantile epileptic encephalopathy with a suppression burst EEG pattern, is an aetiologically heterogeneous condition starting in the first weeks or months of life with intractable seizures and profound developmental disability. Using whole exome sequencing, we identified biallelic DMXL2 mutations in three sibling pairs with Ohtahara syndrome, belonging to three unrelated families. Siblings in Family 1 were compound heterozygous for the c.5135C>T (p.Ala1712Val) missense substitution and the c.4478C>G (p.Ser1493*) nonsense substitution; in Family 2 were homozygous for the c.4478C>A (p.Ser1493*) nonsense substitution and in Family 3 were homozygous for the c.7518-1G>A (p.Trp2507Argfs*4) substitution. The severe developmental and epileptic encephalopathy manifested from the first day of life and was associated with deafness, mild peripheral polyneuropathy and dysmorphic features. Early brain MRI investigations in the first months of life revealed thin corpus callosum with brain hypomyelination in all. Follow-up MRI scans in three patients revealed progressive moderate brain shrinkage with leukoencephalopathy. Five patients died within the first 9 years of life and none achieved developmental, communicative or motor skills following birth. These clinical findings are consistent with a developmental brain disorder that begins in the prenatal brain, prevents neural connections from reaching the expected stages at birth, and follows a progressive course. DMXL2 is highly expressed in the brain and at synaptic terminals, regulates v-ATPase assembly and activity and participates in intracellular signalling pathways; however, its functional role is far from complete elucidation. Expression analysis in patient-derived skin fibroblasts demonstrated absence of the DMXL2 protein, revealing a loss of function phenotype. Patients' fibroblasts also exhibited an increased LysoTracker® signal associated with decreased endolysosomal markers and degradative processes. Defective endolysosomal homeostasis was accompanied by impaired autophagy, revealed by lower LC3II signal, accumulation of polyubiquitinated proteins, and autophagy receptor p62, with morphological alterations of the autolysosomal structures on electron microscopy. Altered lysosomal homeostasis and defective autophagy were recapitulated in Dmxl2-silenced mouse hippocampal neurons, which exhibited impaired neurite elongation and synaptic loss. Impaired lysosomal function and autophagy caused by biallelic DMXL2 mutations affect neuronal development and synapse formation and result in Ohtahara syndrome with profound developmental impairment and reduced life expectancy.
© The Author(s) (2019). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  Ohtahara syndrome; autophagy; developmental and epileptic encephalopathy; neuropathy; progressive disorder

Mesh:

Substances:

Year:  2019        PMID: 31688942     DOI: 10.1093/brain/awz326

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  7 in total

1.  Presynaptic L-Type Ca2+ Channels Increase Glutamate Release Probability and Excitatory Strength in the Hippocampus during Chronic Neuroinflammation.

Authors:  Giorgia Giansante; Antonella Marte; Alessandra Romei; Cosimo Prestigio; Franco Onofri; Fabio Benfenati; Pietro Baldelli; Pierluigi Valente
Journal:  J Neurosci       Date:  2020-08-03       Impact factor: 6.167

2.  A novel variant in DMXL2 gene is associated with autosomal dominant non-syndromic hearing impairment (DFNA71) in a Cameroonian family.

Authors:  Edmond Wonkam-Tingang; Isabelle Schrauwen; Kevin K Esoh; Thashi Bharadwaj; Liz M Nouel-Saied; Anushree Acharya; Abdul Nasir; Suzanne M Leal; Ambroise Wonkam
Journal:  Exp Biol Med (Maywood)       Date:  2021-03-09

3.  Identification of Novel Candidate Genes and Variants for Hearing Loss and Temporal Bone Anomalies.

Authors:  Regie Lyn P Santos-Cortez; Talitha Karisse L Yarza; Tori C Bootpetch; Ma Leah C Tantoco; Karen L Mohlke; Teresa Luisa G Cruz; Mary Ellen Chiong Perez; Abner L Chan; Nanette R Lee; Celina Ann M Tobias-Grasso; Maria Rina T Reyes-Quintos; Eva Maria Cutiongco-de la Paz; Charlotte M Chiong
Journal:  Genes (Basel)       Date:  2021-04-13       Impact factor: 4.096

4.  The Ncoa7 locus regulates V-ATPase formation and function, neurodevelopment and behaviour.

Authors:  Enrico Castroflorio; Joery den Hoed; Daria Svistunova; Mattéa J Finelli; Alberto Cebrian-Serrano; Silvia Corrochano; Andrew R Bassett; Benjamin Davies; Peter L Oliver
Journal:  Cell Mol Life Sci       Date:  2020-12-19       Impact factor: 9.261

5.  Transcriptome Analysis of In Vitro Fertilization and Parthenogenesis Activation during Early Embryonic Development in Pigs.

Authors:  Xin Li; Cheng Zou; Mengxun Li; Chengchi Fang; Kui Li; Zhiguo Liu; Changchun Li
Journal:  Genes (Basel)       Date:  2021-09-22       Impact factor: 4.096

Review 6.  Molecular Mechanism and Regulation of Autophagy and Its Potential Role in Epilepsy.

Authors:  Hanxiao Zhu; Wei Wang; Yun Li
Journal:  Cells       Date:  2022-08-23       Impact factor: 7.666

Review 7.  RAVE and Rabconnectin-3 Complexes as Signal Dependent Regulators of Organelle Acidification.

Authors:  Michael C Jaskolka; Samuel R Winkley; Patricia M Kane
Journal:  Front Cell Dev Biol       Date:  2021-06-24
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.